These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28445579)

  • 41. [White hair turns brown].
    Füessl HS
    MMW Fortschr Med; 2013 Nov; 155(20):34. PubMed ID: 24482928
    [No Abstract]   [Full Text] [Related]  

  • 42. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
    Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
    Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
    [No Abstract]   [Full Text] [Related]  

  • 45. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
    Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
    [No Abstract]   [Full Text] [Related]  

  • 46. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 47. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
    Eglmeier J; Debus D; Schultz ES
    Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
    [No Abstract]   [Full Text] [Related]  

  • 49. Angiosarcoma of the gingiva: Metastasis from a primary tumor of the scalp.
    Yang J; Mei K; Wu C; Wu Y; Xu Y
    Indian J Dermatol Venereol Leprol; 2017; 83(5):626. PubMed ID: 27852985
    [No Abstract]   [Full Text] [Related]  

  • 50. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case of vemurafenib-induced Sweet's syndrome.
    Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
    J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
    Hamid O
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
    [No Abstract]   [Full Text] [Related]  

  • 53. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 54. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1.
    Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Uhara H
    Eur J Dermatol; 2018 Oct; 28(5):705-707. PubMed ID: 30406759
    [No Abstract]   [Full Text] [Related]  

  • 56. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
    Jang S; Venna S
    J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
    [No Abstract]   [Full Text] [Related]  

  • 57. Utilization of immunotherapy among patients with stage 4 melanoma: An analysis of the National Cancer Database from 2012 to 2016.
    Shah PV; Choi JN; Fiessinger L; Nardone B; Nguyen CV; Liszewski W
    J Am Acad Dermatol; 2021 Mar; 84(3):811-814. PubMed ID: 32553633
    [No Abstract]   [Full Text] [Related]  

  • 58. Advanced melanoma in adults: Pembrolizumab as a treatment option.
    Silvinato A; Bernardo WM; Floriano I
    Rev Assoc Med Bras (1992); 2020 May; 66(2):100-107. PubMed ID: 32428140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
    Nakamura Y; Fujisawa Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M
    J Dermatol; 2018 Nov; 45(11):1337-1339. PubMed ID: 30204266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
    Ogawa K; Kamimura K; Terai S
    Hepatology; 2019 Feb; 69(2):914-916. PubMed ID: 30033637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.